Combination therapy before surgery for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment given before surgery to shrink liver cancer and improve outcomes. It combines a liver-directed therapy (HAIC) with two oral drugs (lenvatinib and a PD-1 inhibitor) for people with intermediate-stage liver cancer that can be removed surgically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have not had any prior treatment for your liver cancer (like surgery, radiation, or medicine).
- Your liver function is good (Child-Pugh score 7 or less), and you are in generally good health (ECOG 0 or 1).
- You have intermediate-stage liver cancer (BCLC stage B) that can be safely removed with surgery, confirmed by an MRI.
- A biopsy has confirmed you have hepatocellular carcinoma (a specific type of liver cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new precision approach for people with liver cancer that cannot be removed by surgery. It uses a computer model to analyze your tumor and genetic information to see if combining HAIC (chemotherapy directly into the liver), lenvatinib (a targeted drug), and a PD-1 inhibitor (immunotherapy) is the right treatment for you.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
This trial tests a combination of liver-directed chemotherapy (HAIC), two immunotherapy drugs (iparomlimab and tuvonralimab), and bevacizumab (a drug that blocks blood vessel growth) in people with liver cancer that is too large or numerous for immediate surgery but might become removable after treatment. The goal is to shrink the tumor enough to allow surgery.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.